Kura Oncology, Inc. KURA R2KR3KPHARMA

Q: What is the current share price of Kura Oncology, Inc. (KURA)?

As of 2026-10-23 16:27 PDT, Kura Oncology, Inc. (KURA) trades at $9.61 on NasdaqGS. Its 52-week range is $6.49 to $13.59.

Q: What is the market capitalisation of KURA?

Kura Oncology, Inc. (KURA) has a market capitalisation of $854.91M on NasdaqGS.

Q: What is the P/E ratio of KURA?

KURA trades at a trailing price-to-earnings (P/E) ratio of -2.85. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 21.56.

Q: Is KURA a good stock to buy?

This page provides a data-driven analysis of Kura Oncology, Inc. (KURA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://kuraoncology.com

Company Profile ↓

$9.61

+48.07% 1Y

Mkt Cap$854.91M

P/E-2.85

P/B21.56

52W High$13.59

52W Low$6.49

Book Value$0.54

EPS (TTM)$-3.37

Company Overview

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Recent Developments

Dec 2025 Revenue of $67.48M (+25.2% YoY); net profit $-278.67M.
Trailing 12 Months Year-on-year growth — revenue +36.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-
1 Year:	36.50%

Stock Price Performance

1 Year:	+48.07%
6 Months:	+3.78%
3 Months:	-5.32%
1 Month:	-11.51%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 44% of range

$6.49 $13.59

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)37.88 · Neutral

Price Performance

1M-11.51%

3M-5.32%

6M+3.78%

1Y+48.07%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading 29.3% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-2.85

Industry PE

25.45

Forward P/E

-4.18

PEG Ratio

Book Value

$0.54

Price to Book

21.56

P/S

13.51

EV/EBITDA

-1.73

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

Revenue (YoY)

36.50%

Earnings (YoY)

Profitability & Returns

ROCE

-48.86%

ROE

ROA

-31.30%

Profit Margin

0.00%

Op Margin

Gross Margin

EPS (Latest Qtr)

$-0.83

EPS (TTM)

$-3.37

Balance Sheet & Liquidity

Debt/Equity

0.50

Quick Ratio

4.50

Current Ratio

4.73

Debt

$24.45M

Total Assets

$652.55M

Current Assets

Working Capital

Ownership

Promoter Holding

1.40%

Chg in Prom Hold

0.01%

FII / Inst Holding

100.08%

Chg in FII Hold

0.31%

Financial Snapshot

Enterprise Value

$854.91M

Total Revenue (TTM)

$77.22M

EBITDA

$-316.80M

Free Cash Flow

$-165.88M

Operating Cash Flow

$-111.76M

Shares Outstanding

88.96M

Gross Margin

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	KURA Kura Oncology, Inc. R2KR3KPHARMA	9.61	-2.85	$854.91M	0.00%	-48.86%	-	-	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,273.46	42.83	$1.14T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	263.81	30.60	$635.76B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	285.64	80.69	$504.76B	2.54%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	418.09	26.85	$375.28B	2.47%	9.74%	14.15%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPXR3KPHARMA	145.27	116.22	$358.41B	2.31%	-	6.96%	5.64%	10.01%
7	NVS Novartis AG PHARMA	151.12	22.83	$287.24B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	171.49	25.63	$265.96B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	673.82	36.30	$249.14B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.11M	15.29M	20.75M	17.34M	18.27M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	262.00K
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.11M	-	-	-	18.00M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78.81M	87.95M	100.75M	103.55M	96.82M
Operating Income	-4.14K	-5.24K	-4.76K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-54.45M	-56.40M	-59.88M	-64.70M	-72.67M	-80.00M	-86.27M	-78.81M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-56.58M	-65.51M	-73.56M	-80.18M	-72.63M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	382.00K	391.00K	393.00K	346.00K	336.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-57.20M	-66.12M	-74.12M	-80.93M	-73.33M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	226.00K	0	0	71.00K	8.00K
Net Income	-5.77K	-6.89K	-6.43K	-4.48M	-5.58M	-6.09M	-6.63M	-6.66M	-6.93M	-7.53M	-7.82M	-9.33M	-14.60M	-14.74M	-15.01M	-16.10M	-13.94M	-14.94M	-16.39M	-17.86M	-19.21M	-20.49M	-23.77M	-30.69M	-33.66M	-33.37M	-32.45M	-34.77M	-35.50M	-34.07M	-37.17M	-38.60M	-49.52M	-50.84M	-54.40M	-57.43M	-66.12M	-74.12M	-81.00M	-73.33M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.51	-0.50	-0.49	-0.52	-0.53	-0.50	-0.53	-0.50	-0.59	-0.59	-0.63	-0.66	-0.75	-0.85	-0.92	-0.83
R&D Expense	-	-	-	2.60M	3.35M	3.64M	-	-	-	-	-	-	-	-	-	-	10.38M	11.44M	12.54M	-	12.57M	13.70M	16.60M	20.32M	21.07M	22.37M	20.91M	24.26M	24.97M	25.19M	28.18M	29.33M	36.27M	39.73M	41.70M	55.97M	62.78M	67.91M	-	65.26M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	53.88M	67.48M
Operating Income	-	-	-	-20.51K	-23.44K	-22.34K	-22.73K	-23.91K	-	-	-	-	-	-	-	-139.87M	-165.80M	-193.19M	-303.63M
Net Income	-14.98K	-33.62K	-20.00K	-22.39K	-27.04K	-27.32K	-28.61K	-30.73K	-22.62M	-27.56M	-35.43M	-60.45M	-63.14M	-89.62M	-130.47M	-135.84M	-152.63M	-173.98M	-278.67M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.69	-1.97	-2.03	-2.08	-2.02	-3.18
R&D Expense	-	-	-	-	-	-	-	-	-	-	26.43M	46.79M	47.83M	60.40M	84.72M	92.81M	115.23M	169.97M	251.07M

Balance Sheet (Annual)

Figures in USD.

Metric	Nov 2007	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Sep 2011	Dec 2011	Sep 2012	Dec 2012	Dec 2013	Aug 2014	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	-	-	-	8.30K	9.07K	-	1.38M	87.26M	69.82M	95.85M	182.38M	241.97M	647.21M	534.05M	456.31M	448.94M	760.16M	738.36M
Total Equity	0	35.02K	1.40K	-18.60K	-40.99K	-	-68.03K	-	-95.35K	-123.96K	0	-3.43M	82.10M	56.88M	79.86M	160.99M	218.78M	610.90M	506.61M	420.28M	397.27M	413.64M	174.13M
Cash & Equivalents	0	-	-	11.14K	26.90K	6.16K	4.22K	5.59K	4.80K	6.57K	-	1.12M	15.44M	9.72M	11.43M	16.12M	26.14M	325.49M	90.67M	51.80M	37.32M	224.46M	149.10M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	7.32M	5.57M	7.50M	7.25M	4.25M	-	9.16M	9.33M	6.92M	9.71M
Total Liabilities	-	-	-	-	-	-	-	-	103.65K	133.03K	-	4.81M	5.16M	12.95M	15.99M	21.39M	23.19M	36.31M	27.44M	36.03M	51.66M	346.52M	564.23M
Current Liabilities	-	-	-	-	70.39K	-	74.75K	-	103.65K	-	-	3.02M	5.05M	5.45M	10.03M	13.62M	15.56M	26.02M	22.45M	24.06M	35.26M	78.71M	116.97M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-19.24K	-22.68K	-24.42K	-23.23K	-15.96K	-	-28.44M	-48.66M	-54.76M	-69.83M	-104.55M	-110.06M	-124.82M	134.32M	-64.06M
Investing Cash Flow	-	-	-	-	-	-	-23.42M	-79.30M	-46.33M	-99.94M	-126.83M	32.63M	15.56M	-101.59M	-13.10M
Financing Cash Flow	35.00K	0	25.00K	25.00K	15.00K	-	53.57M	132.64M	111.10M	469.33M	-3.44M	38.56M	94.78M	154.42M	1.79M
Capital Expenditure	-	-	-	-	-	-64.00K	-	-	-	-2.17M	-1.15M	-626.00K	-168.00K	-472.00K	-6.64M
Free Cash Flow	-	-	-	-	-	-	-	-	-	-72.00M	-105.70M	-110.69M	-124.99M	133.84M	-70.70M

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-358.5%	-449.9%
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-322.9%	-412.9%
ROE %	-42.8%	-2,401.6%	107.5%	54.6%	39.7%	28.6%	23.1%	0.9%	-27.6%	-48.5%	-44.4%	-37.5%	-28.9%	-14.7%	-25.8%	-32.3%	-38.4%	-42.1%	-160.0%
ROCE %	-	-	-	-	-	23.4%	-	1.5%	-	-	-	-	-	-	-	-32.4%	-40.1%	-28.4%	-48.9%

Shareholding Pattern

Insiders

1.40%

Institutions

100.08%

Public Float

101.50%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	11.81%	10.51M	$111.40M
2	Montanova Capital LLC	9.64%	8.58M	$90.90M
3	BVF Inc.	9.49%	8.45M	$89.53M
4	State Street Corporation	5.99%	5.33M	$56.49M
5	Vanguard Capital Management LLC	4.40%	3.92M	$41.51M
6	Armistice Capital, LLC	4.13%	3.68M	$38.99M
7	AQR Capital Management, LLC	3.51%	3.13M	$33.14M
8	Goldman Sachs Group Inc	2.55%	2.27M	$24.01M
9	Geode Capital Management, LLC	2.51%	2.23M	$23.64M
10	Alethea Capital Management, LLC	2.44%	2.17M	$22.98M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KURA

Google News ue, 01 Sep 2026

KURA Stock Gains 37.6% in a Month: Here's What You Need to Know - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPOWRjTm03THBzdjFEYkxOcERVbXFFU3ktUzlvZ3d1Y2ZNTS1ONDJjcW9KOHpER2g0eHNaUzc5NE1EY1NCTlRCZFlvN0p2eHdSOVZjb2kzS2V5a3pCdS0zYzFUUEhCeHlrUFpBc1ZiR2R5cG5IVkhTYWlGYnF2UDlpU3NYemp2aTVqYWpxZ0…

Google News ue, 25 Aug 2026

KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares — Retail Wonders If Wilson Is Following Moderna CEO’s Playbook - Stocktwits

<a href="https://news.google.com/rss/articles/CBMikAJBVV95cUxQWkVtVmphcTBfTXNrQ1U0LU4wT2k3WTN3Zi1BQ2UxdURHbW4yb3JGZUlZVWttRUJ6ZHFmcS0xVnFCYURTZk1iM0RCUkZuTlZDV1kwZkZvMHpPeHp4NWJ4SHYxcE5SUXVXdDVvNnlCU3c0VzBTa0FJREZiZGgxWThnRXcxT2dsM0tlYjBaMz…

Google News hu, 27 Aug 2026

Cancer Biotech Kura Oncology Rallies to New High After CEO’s Stock Purchase - Barron's

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE1NWXpLVjlJMXh6b2VwOXNhTXFsOHE0SGZnMWhQVHNodWVvbkM3UE83dVljdExwUk9VbWJtZ21hUGFQTDdjVm9QaEJ5U2NVVlZTWTNGdFNZcktIZ2NLVUpVYVZPNjBFTHdZTVBONFA4R3lCM0I3TExLR3Z2NA?oc=5" target="_blank">C…

Google News Wed, 09 Sep 2026

Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes - Pharmaceutical Executive

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQaXJRN2dJbXJPci1Va1Q5VlRYQnNiYVk1V2VaZlo4WS1jVFZmZnBTQTRsU0E0aFExY1pjUVAxdm9KUGhqV3dWVk5JTGpLOTNJb0REVDdKYmlna0IxUl90WFhZdzhOajdCMVluRWRyNGhtdlBaOVZCNzhrajAtMXByNHdfUGtlOTV5S05zVl…

Google News hu, 21 May 2026

Kura Sushi's stock climbs after Trump investment - SeafoodSource

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOQUhpdmpmMzEtZGVlLW4wZ0lWSV9tOGVnd1NnTzdZNzExdnlpOVhHcUlFd2tzMHNjUU9MZ2w4N0JkZWxITko1aUpUNW82cHRub0dGdnNVTUtmbElQV25jVUQ4ZXY2SmR3S2w3RkQ3WkxMX0tmd3U1aWJZZXA3SkdmTGhuLV9HU0ZZNmNvZ1…

Google News Wed, 14 Oct 2026

Kura Oncology (NasdaqGS:KURA) Stock Forecast & Analyst Predictions - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPdHl6MUVuM1c5WFE0OTJfcHRBZUtKaTlWM3hHVjR2RWJxSm9HWXo2TWxuLXl4Zmo5Tk1MamVDamVERk9YN0tLY3BjQ1pfUEpsNDdBeEgta3Y3enJGMk1ITWt6SXhXX01Jd0k1OFV1UTY1bmtrczhyRk1tN0Y5NXQ3TUhTcVU1NlotYUNOWn…

KURA — Frequently Asked Questions

What is the current share price of Kura Oncology, Inc. (KURA)?

As of 2026-10-23 16:27 PDT, Kura Oncology, Inc. (KURA) trades at $9.61 on NasdaqGS. Its 52-week range is $6.49 to $13.59.

What is the market capitalisation of KURA?

Kura Oncology, Inc. (KURA) has a market capitalisation of $854.91M on NasdaqGS.

What is the P/E ratio of KURA?

KURA trades at a trailing price-to-earnings (P/E) ratio of -2.85. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 21.56.

Is KURA a good stock to buy?

This page provides a data-driven analysis of Kura Oncology, Inc. (KURA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Kura Oncology, Inc. KURA R2KR3KPHARMA

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

KURA Stock Gains 37.6% in a Month: Here's What You Need to Know - Yahoo Finance

KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares — Retail Wonders If Wilson Is Following Moderna CEO’s Playbook - Stocktwits

Cancer Biotech Kura Oncology Rallies to New High After CEO’s Stock Purchase - Barron's

Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes - Pharmaceutical Executive

Kura Sushi's stock climbs after Trump investment - SeafoodSource

Kura Oncology (NasdaqGS:KURA) Stock Forecast & Analyst Predictions - Simply Wall Street

KURA — Frequently Asked Questions

What is the current share price of Kura Oncology, Inc. (KURA)?

What is the market capitalisation of KURA?

What is the P/E ratio of KURA?

Is KURA a good stock to buy?

Explore More